Madan Jagasia, Obsidian Therapeutics CEO
April 3, 2024 11:27 AM EDTUpdated 11:42 AM
Financing
Cell/Gene Tx

Ob­sid­i­an Ther­a­peu­tics rakes in $160M for sol­id tu­mor cell ther­a­py pro­gram

Lei Lei Wu

News Reporter

Ob­sid­i­an Ther­a­peu­tics an­nounced Wednes­day that it raised $160.5 mil­lion to push its tu­mor-in­fil­trat­ing lym­pho­cyte (TIL) pro­gram fur­ther in clin­i­cal tri­als. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times